Pre-clinical Characterization of MOD-4023, a Long-Acting Growth Hormone. See abstract for more information.
SAT-647: Highly Producing Fed-Batch Manufacturing Process of Long-Acting Human Growth Hormone (MOD-4023) in CHO Cells. See abstract for more information.
SUN-637: Development of a Population Pharmacokinetic and Pharmacodynamic Model Following a Phase II Study of MOD-4023 in Growth Hormone Deficient Adults. See abstract for more information.
ENDO 2013 abstracts are available online at: https://endo.confex.com/endo/2013endo/webprogram/COP.html.
ENDO 2013, the 95th Annual Meeting & Expo of the Endocrine Society, is being held June 15-18, 2013, in San Francisco. For more information, visit: https://www.endocrine.org/meetings/endo-annual-meeting/endo-2013#/nav/.
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is developing a long-acting version of human growth hormone, which is
|SOURCE PROLOR Biotech, Inc.|
Copyright©2012 PR Newswire.
All rights reserved